Cardiology, Diabetes & Nephrology at the Limits Canada 2021
 

Programme


Overall Meeting Learning Objective:

This meeting will discuss the latest thinking in Cardiology, Diabetes and Nephrology. World experts will present their thoughts and ideas in their specific area of expertise, taking their presentation to the limits of our knowledge to-date, and the considering of likely future developments.

Individual Session Learning Objectives:

  • Participants will be able to consider surprising findings from clinical trials in cardiology, diabetes & nephrology.
  • Participants will be able to evaluate 100 years of insulin; have we reached the limits?
  • Participants will be able to identify primordial cardiology in youth – what are the limits?
  • Participants will be able to consider controlling cardiovascular risk factors in 2021-beyond glucose.
  • Participants will be able to analyse the debate: Should metformin be first line therapy?
  • Participants will be able to recognize new genetics & therapies of dyslipidemias.
  • Participants will be able to consider the clinical benefit and biology of modern therapy for type 2 diabetes: GLP-1 analogues.
  • Participants will be updated about the science of obesity, where might this lead clinical practice?
  • Participants will be able to analyse the debate: Would you entrust your heart to a nephrologist or your kidneys to a cardiologist?
  • Participants will be able to examine SGLT2i cardiorenal mechanisms in diabetes and beyond.
  • Participants will be able to consider the Cardiovascular mechanisms of GLP-1 and its emerging co-agonist partners.
  • Participants will be able to judge, are the limits blurring between cardiovascular disease, aging, and cancer?
  • Participants will be able to define Heart failure therapy – extending the limits!

 


Chairs:

Professor Derek YellonProfessor Daniel DruckerDr Mansoor HusainDr Gary Lewis , Professor Alice ChengProfessor John Cunningham,
Dr Peter LibbyProfessor Marc PfefferProfessor Theresa McDonaghDr Richard HortonProfessor Brian RaynerProfessor Stephanie Baldeweg


Wednesday, 3 March
All times EST
6:00 pm Welcome to the event
The Chairs: Derek Yellon & Dan Drucker
 
6:05 pm Session Chairs: Derek Yellon & Dan Drucker
The Lancet Lecture: 100 years of insulin - have we reached the limits?
Professor Bernard Zinman
University of Toronto, Canada
 
  Controlling cardiovascular risk factors in 2021 - beyond glucose
Professor Lawrence Leiter
University of Toronto, Canada
 
  The new genetics & therapies of dyslipidemias
Professor Robert A Hegele
Robarts Research Institute, Ontario, Canada
 
  Q & A
Chairs: Derek Yellon & Dan Drucker
Professor Bernard Zinman, Professor Lawrence Leiter & Professor Robert A Hegele
 
6:50 pm Session Chairs: Marc Pfeffer & John Cunningham
Cardiac atheroma at the limits - are we fighting the final battle?
Professor Peter Libby
Brigham and Women's Hospital, Harvard Medical School, Boston, USA
 
  Primordial cardiology in youth – what are the limits?
Professor John Deanfield
University College London, UK
 
  Q & A
Chairs: Marc Pfeffer & John Cunningham
Professor Peter Libby, & Professor John Deanfield,
 
  Industry Satellite Symposium: Pfizer
 
7:50 pm Session Chairs: Stephanie Baldeweg & Theresa McDonagh
Debate:
Should metformin be first line therapy?
  No: Professor Alice Cheng
University of Toronto, Canada
Yes: Professor Cliff Bailey
Aston University, UK
 
8:20 pm Close
Chairs: Derek Yellon & Dan Drucker
 
8:30 pm End

 
Thursday, 4 March
All times EST
6:00 pm Welcome to the event
The Chairs: Gary Lewis & Alice Cheng
 
6:03 pm Session Chairs: Gary Lewis & Alice Cheng
Cardiovascular mechanisms of GLP-1 and its emerging co-agonist partners
Professor Daniel Drucker
University of Toronto, Canada
 
  Clinical benefit of modern therapy for type 2 diabetes - GLP-1 analogues
Professor Mansoor Husain
University of Toronto, Canada
 
  The science of obesity, where might this lead clinical practice?
Professor Sean Wharton
McMaster University & Wharton Medical Clinic, Canada
 
  Q & A
Chairs: Gary Lewis & Alice Cheng
Professor Daniel Drucker, Professor Mansoor Husain, & Professor Sean Wharton
 
6:40 pm Session Chairs: Brian Rayner & Peter Libby
SGLT2i Cardiorenal mechanisms in diabetes and beyond
Professor Julie Lovshin
University of Toronto, Canada
 
  Heart failure therapy – extending the limits!
Professor Theresa McDonagh
King’s College London, UK
 
  Surprising findings from clinical trials – cardiology, diabetes & nephrology
Professor Marc Pfeffer
Harvard University, Boston, USA
 
  Q & A
Chairs: Brian Rayner & Peter Libby
Professor Julie Lovshin, Professor Theresa McDonagh & Professor Marc Pfeffer
 
7:20 pm Industry Satellite Symposium: Novo Nordisk
 
7:50 pm Session Chairs: John Cunningham & Marc Pfeffer
Debate:
Would you entrust your heart to a nephrologist or your kidneys to a cardiologist?
  Professor Philip Kalra (nephrologist)
University Manchester, UK
Professor Paul Kalra (cardiologist)
University of Portsmouth, UK
 
8:20 pm Close
Chairs: Derek Yellon & Dan Drucker
 
8:30 pm End

Support

CDNATL Canada 2021 is financially supported by the Pharmaceutical Industry and Academia. The Pharmaceutical Industry’s financial support for the event is restricted primarily to facilitating the development of the independent medical/scientific content and speaker fees. Funds from the Pharmaceutical Industry have not been used for travel, accommodation or any other ancillary expenses for participants. Supporters have had no input into the content of the independent scientific sessions or any other aspect of the meeting. Supporters are listed here.